Download MendeleyDiscovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.
Wu, Y.J., Guernon, J., Rajamani, R., Toyn, J.H., Ahlijanian, M.K., Albright, C.F., Muckelbauer, J., Chang, C., Camac, D., Macor, J.E., Thompson, L.A.(2016) Bioorg Med Chem Lett 26: 5729-5731
- PubMed: 27816517
- DOI: https://doi.org/10.1016/j.bmcl.2016.10.055
- Primary Citation of Related Structures:
5TOL - PubMed Abstract:
This Letter describes the synthesis and structure-activity relationships of a series of furo[2,3-d][1,3]thiazinamine BACE1 inhibitors. The co-crystal structure of a representative thiazinamine 2e bound with the BACE1 active site displayed a binding mode driven by interactions with the catalytic aspartate dyad and engagement of the biaryl amide toward the S1 and S3 pockets. This work indicates that furo[2,3-d]thiazine can serve as a viable bioisostere of the known furo[3,4-d]thiazine.
Organizational Affiliation:
Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA. Electronic address: Yong-Jin.Wu@bms.com.
